Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208

ChemMedChem

Volumn 6, Issue 9, 2011, Pages 1739-1745

  Aldrich, Jane V ^a   Kulkarni, Santosh S ^a,d   Senadheera, Sanjeewa N ^a   Ross, Nicolette C ^b   Reilley, Kate J ^b   Eans, Shainnel O ^b   Ganno, Michelle L ^b   Murray, Thomas F ^c   McLaughlin, Jay P ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SYNGENE INTERNATIONAL LTD   (India)

Author keywords

opioid receptor antagonists; Analgesics; Peptides; Structure activity relationships

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ALANINE; CJ 15208; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALTRINDOLE; NARCOTIC ANALGESIC AGENT; PHENYLALANINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYCLIZATION; DRUG ANTAGONISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALANINE; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; LIGANDS; MICE; MICE, INBRED C57BL; PEPTIDES, CYCLIC; PHENYLALANINE; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052084062     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100113     Document Type: Article

References (39)

1. J. V. Aldrich, J. P. McLaughlin, AAPS J. 2009, 11, 312-322.
2. S. D. Mague, A. M. Pliakas, M. S. Todtenkopf, H. C. Tomasiewicz, Y. Zhang, W. C. J. Stevens, R. M. Jones, P. S. Portoghese, W. A. J. Carlezon, J. Pharmacol. Exp. Ther. 2003, 305, 323-330.
3. J. P. McLaughlin, M. Marton-Popovici, C. Chavkin, J. Neurosci. 2003, 23, 5674-5683.
4. P. M. Beardsley, J. L. Howard, K. L. Shelton, F. I. Carroll, Psychopharmacology (Berlin) 2005, 183, 118-126.
5. A. T. Knoll, E. G. Meloni, J. B. Thomas, F. I. Carroll, W. A. Carlezon, Jr., J. Pharmacol. Exp. Ther. 2007, 323, 838-845.
6. V. A. Redila, C. Chavkin, Psychopharmacology (Berlin) 2008, 200, 59-70.
7. R. B. Rothman, D. A. Gorelick, S. J. Heishman, P. R. Eichmiller, B. H. Hill, J. Norbeck, J. G. Liberto, J. Subst. Abuse Treat. 2000, 18, 277-281.
8. G. Gerra, A. Fantoma, A. Zaimovic, J. Psychopharmacol. 2006, 20, 806-814.
9. M. D. Metcalf, A. Coop, AAPS J. 2005, 7, E704-722.
10. P. Horan, J. Taylor, H. I. Yamamura, F. Porreca, J. Pharmacol. Exp. Ther. 1992, 260, 1237-1243.
11. F. I. Carroll, L. S. Harris, M. D. Aceto, Eur. J. Pharmacol. 2005, 524, 89-94.
12. Q. Wan, T. F. Murray, J. V. Aldrich, J. Med. Chem. 1999, 42, 3011-3013.
13. Y. Lu, T. M.-D. Nguyen, G. Weltrowska, I. Berezowska, C. Lemieux, N. N. Chung, P. W. Schiller, J. Med. Chem. 2001, 44, 3048-3053.
14. M. A. Bennett, T. F. Murray, J. V. Aldrich, J. Med. Chem. 2002, 45, 5617-5619.
15. B. S. Vig, T. F. Murray, J. V. Aldrich, J. Med. Chem. 2003, 46, 1279-1282.
16. K. A. Patkar, X. Yan, T. F. Murray, J. V. Aldrich, J. Med. Chem. 2005, 48, 4500-4503.
17. J. V. Aldrich, K. A. Patkar, J. P. McLaughlin, Proc. Natl. Acad. Sci. USA 2009, 106, 18396-18401.
18. T. Saito, H. Hirai, Y.-J. Kim, Y. Kojima, Y. Matsunaga, H. Nishida, T. Sakakibara, O. Suga, T. Sujaku, N. Kojima, J. Antibiot. 2002, 55, 847-854.
19. S. S. Kulkarni, N. C. Ross, J. P. McLaughlin, J. V. Aldrich, Adv. Exp. Med. Biol. 2009, 611, 269-270.
20. N. C. Ross, S. S. Kulkarni, J. P. McLaughlin, J. V. Aldrich, Tetrahedron Lett. 2010, 51, 5020-5023.
21. N.C. Ross, K.J. Reilley, T.F. Murray, J.V. Aldrich, J.P. McLaughlin, Br. J. Pharmacol., DOI:.
22. R. E. Dolle, M. Michaut, B. Martinez-Teipel, P. R. Seida, C. W. Ajello, A. L. Muller, R. N. DeHaven, P. J. Carroll, Bioorg. Med. Chem. Lett. 2009, 19, 3647-3650.
23. S. Arttamangkul, J. E. Ishmael, T. F. Murray, D. K. Grandy, G. E. DeLander, B. L. Kieffer, J. V. Aldrich, J. Med. Chem. 1997, 40, 1211-1218.
24. K. J. Reilley, M. Giulianotti, C. T. Dooley, A. Nefzi, J. P. McLaughlin, R. A. Houghten, AAPS J. 2010, 12, 318-329.
25. M. Ohsawa, H. Mizoguchi, M. Narita, H. Nagase, J. P. Kampine, L. F. Tseng, J. Pharmacol. Exp. Ther. 2001, 298, 592-597.
26. M. Ohsawa, M. Shiraki, H. Mizoguchi, M. Narita, K. Kawai, H. Nagase, E. Y. Cheng, L. F. Tseng, Neurosci. Lett. 2001, 316, 1-4.
27. S. Sakurada, T. Hayashi, M. Yuhki, T. Orito, J. E. Zadina, A. J. Kastin, T. Fujimura, K. Murayama, C. Sakurada, T. Sakurada, M. Narita, T. Suzuki, K. Tan-no, L. F. Tseng, Eur. J. Pharmacol. 2001, 427, 203-210.
28. H. H. Szeto, Y. Soong, D. Wu, X. Qian, G. M. Zhao, J. Pharmacol. Exp. Ther. 2003, 305, 696-702.
29. H. Mizoguchi, G. Bagetta, T. Sakurada, S. Sakurada, Peptides 2011, 32, 421-427.
30. M. Shimoyama, N. Shimoyama, G. M. Zhao, P. W. Schiller, H. H. Szeto, J. Pharmacol. Exp. Ther. 2001, 297, 364-371.
31. B. S. Vig, J. V. Aldrich, Aldrichimica Acta 2004, 37, 2.
32. W. C. Chan, P. D. White, Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press, New York, 2000, pp.41-76.
33. Y. C. Cheng, W. H. Prusoff, Biochem. Pharmacol. 1973, 22, 3099-3108.
34. J. F. Siebenaller, T. F. Murray, Biol. Bull.-US 1999, 197, 388-394.
35. H. O. Schild, Br. J. Pharmacol. Chemother. 1947, 2, 189-206.
36. J. S. Mogil, B. Kest, B. Sadowski, J. K. Belknap, J. Pharmacol. Exp. Ther. 1996, 276, 532-544.
37. B. Kest, E. Hopkins, C. A. Palmese, M. Adler, J. S. Mogil, Pharmacol. Biochem. Behav. 2002, 73, 821-828.
38. T. J. Haley, W. G. McCormick, Br. J. Pharmacol. Chemother. 1957, 12, 12-15.
39. J. P. McLaughlin, K. P. Hill, Q. Jiang, A. Sebastian, S. Archer, J. M. Bidlack, J. Pharmacol. Exp. Ther. 1999, 289, 304-311.